Year None202420232022202120202019201820172016 March 6, 2024 Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting Go to February 14, 2024 Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update Go to February 13, 2024 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Go to January 12, 2024 Medicenna Announces Appointment of New Auditor Go to January 9, 2024 Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab Go to Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4
March 6, 2024 Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting Go to
February 14, 2024 Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update Go to
February 13, 2024 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors Go to
January 9, 2024 Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab Go to